Cost‐effectiveness of long‐acting insulin analogues vs intermediate/long‐acting human insulin for type 1 diabetes: A population‐based cohort followed over 10 years-Reference-Cited by-同舟云学术

Cost‐effectiveness of long‐acting insulin analogues vs intermediate/long‐acting human insulin for type 1 diabetes: A population‐based cohort followed over 10 years

Published:2020-01-23 Issue:5 Volume:86 Page:852-860
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Lee Tsung‐Ying¹^ORCID,Kuo Shihchen²,Yang Chen‐Yi¹,Ou Huang‐Tz¹^ORCID

Affiliation:

1. School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of MedicineNational Cheng Kung University Tainan Taiwan

2. Division of Metabolism, Endocrinology and Diabetes, Department of Internal MedicineUniversity of Michigan Ann Arbor Michigan

Funder

Ministry of Science and Technology, Taiwan

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14188

Reference58 articles.

1. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

2. 3: Preventing complications of diabetes

3. Vascular Complications of Diabetes

4. Economic Costs of Diabetes in the U.S. in 2012

5. Incidence and prevalence rates of diabetes mellitus in Taiwan: Analysis of the 2000–2009 Nationwide Health Insurance database

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimation of the number needed to treat, the number needed to be exposed, and the exposure impact number with instrumental variables;Epidemiologic Methods;2024-01-01

2. The global burden of disease attributable to metabolic risks in 204 countries and territories from 1990 to 2019;Diabetes Research and Clinical Practice;2023-02

3. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update;Endocrine Practice;2022-10

4. The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review;Value in Health;2022-07

5. The number needed to treat adjusted for explanatory variables in regression and survival analysis: Theory and application;Statistics in Medicine;2022-04-26